A widely recognized limitation of molecular prediction models is their reliance on structures observed in the training data, resulting in poor generalization to out-of-distribution compounds. Yet in drug discovery, the compounds most critical for advancing research often lie beyond the training set, making the bias toward the training data particularly problematic. This mismatch introduces substantial covariate shift, under which standard deep learning models produce unstable and inaccurate predictions. Furthermore, the scarcity of labeled data—stemming from the onerous and costly nature of experimental validation—further exacerbates the difficulty of achieving reliable generalization. To address these limitations, we propose a novel meta-learning-based approach that leverages unlabeled data to interpolate between in-distribution (ID) and out-of-distribution (OOD) data, enabling the model to meta-learn how to generalize beyond the training distribution. We demonstrate significant performance gains over state-of-the-art methods on challenging real-world datasets that exhibit substantial covariate shift.